geoffreyDow-prof.jpg

Geoffrey Dow

60P Pharmaceuticals

As a co-founder and CEO of 60P, Dr. Geoffrey Dow brings more than 20 years of product development experience in tropical diseases and has an extensive publication and patent history. His decades of hands-on experience include 13 years in key leadership and advisory roles in the antimalarial drug development program at the Walter Reed Army Institute of Research and at the U.S. Army Medical Materiel Development Activity.

At 60P, Geoff is integrally involved in management of the tafenoquine development program. He was awarded a PhD in veterinary and biomedical sciences by Murdoch University, Australia, and received his MBA from the University of Maryland, USA. As an inventor and contributor on eight patent applications, Geoff’s ultimate goal is the discovery, development, and regulatory approval of one or more drugs for a tropical disease.